J-F Stalder1, H Aubert1, E Anthoine2, M Futamura3, D Marcoux4, M-A Morren5, M Trzeciak6, Z Szalai7, K Veres7, M Deleuran8, C Vestergaard8, F Boralevi9, C-Y Chu10, L De Raeve11, Å Svensson12, R Fölster-Holst13, M Buchner13, R Takaoka14, V Aoki14, P Chernyshov15, L Chernyshova16, D F Murrell17, C Zhao17, C D Mckinster18, L Von Kobyletzky19, L Eichenfield20, C Totri21, P Lio22, J Seneschal9, L Moret23, S Barbarot1. 1. Department of Dermatology, Nantes University Hospital, Nantes, France. 2. EA 4275 SPHERE "Methods in Patient-Centered Outcomes & Health Research", University of Nantes, Nantes, France. 3. Division of Allergy, National Center for Child Health and Development, Tokyo, Japan. 4. Department of Dermatology, Sainte-Justine University Hospital, Montreal, Quebec, Canada. 5. Department of Dermatology, Leuven University Hospital, Leuven, Belgium. 6. Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Poland. 7. Department of Dermatology, Heim Pál Children's Hospital, Budapest, Hungary. 8. Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark. 9. Department of Dermatology, Bordeaux CHU, Bordeaux, France. 10. Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. 11. Department of Dermatology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium. 12. Department of Dermatology, Malmö University Hospital, Malmö, Sweden. 13. Department of Dermatology, Venereology und Allergology, Tagesklinik Univ-Hautklinik, Kiel, Germany. 14. Department of Dermatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 15. Department of Dermatology, Bogomolets National Medical University, Kiev, Ukraine. 16. Department of Pediatric Infectious Diseases, Clinical Immunology of the National Medical Academy of Postgraduate Education, Kiev, Ukraine. 17. Department of Dermatology, St George Hospital, Sydney, Australia. 18. Department of Dermatology, Hospital Médica sur Puente de Piedra, Mexico City, Mexico. 19. Department of Dermatology, Skåne University Hospital, Malmö, Sweden. 20. Department of Dermatology, UC San Diego Rady Children's Hospital, San Diego, CA, USA. 21. Department of Dermatology, State University of New York, Downstate, Brooklyn, NY, USA. 22. Chicago Integrative Eczema Center, Chicago, IL, USA. 23. Department of Public Health, Nantes University Hospital, Nantes, France.
Abstract
BACKGROUND: Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined the feasibility of applying the validated TOPICOP score for assessing TCS phobia across different countries. METHODS: This was a prospective multicentre feasibility study conducted in 21 hospitals in 17 countries. Patients >3 months of age with atopic dermatitis or their parents or legal representatives completed a validated translation of the TOPICOP questionnaire in the country's native language. Respondents also completed questionnaires collecting opinions about the feasibility and acceptability of the TOPICOP questionnaire. RESULTS: A total of 1564 participants in 15 countries were included in the analysis. 81% of respondents considered the questions clear or very clear, and 79% reported that it took less than 5 minutes to complete. Each of the individual items in the TOPICOP questionnaire was considered to be not at all difficult to answer by 49% to 74% of participants. The mean global TOPICOP score was 44.7%±20.5. Mean TOPICOP subscores were 37.0±22.8% for knowledge and beliefs, 54.7±27.8% for fears and 50.1±29.1% for behaviours. Global scores and subscores differed between countries, although the subscores did not always vary in parallel, suggesting different levels of TCS phobia and different drivers for each country. CONCLUSIONS: The TOPICOP score can be feasibly applied across countries and may therefore be useful for obtaining qualitative and quantitative data from international studies and for adapting patient education and treatment.
BACKGROUND: Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined the feasibility of applying the validated TOPICOP score for assessing TCS phobia across different countries. METHODS: This was a prospective multicentre feasibility study conducted in 21 hospitals in 17 countries. Patients >3 months of age with atopic dermatitis or their parents or legal representatives completed a validated translation of the TOPICOP questionnaire in the country's native language. Respondents also completed questionnaires collecting opinions about the feasibility and acceptability of the TOPICOP questionnaire. RESULTS: A total of 1564 participants in 15 countries were included in the analysis. 81% of respondents considered the questions clear or very clear, and 79% reported that it took less than 5 minutes to complete. Each of the individual items in the TOPICOP questionnaire was considered to be not at all difficult to answer by 49% to 74% of participants. The mean global TOPICOP score was 44.7%±20.5. Mean TOPICOP subscores were 37.0±22.8% for knowledge and beliefs, 54.7±27.8% for fears and 50.1±29.1% for behaviours. Global scores and subscores differed between countries, although the subscores did not always vary in parallel, suggesting different levels of TCS phobia and different drivers for each country. CONCLUSIONS: The TOPICOP score can be feasibly applied across countries and may therefore be useful for obtaining qualitative and quantitative data from international studies and for adapting patient education and treatment.
Authors: Tiago Fernandes Gomes; Katarina Kieselova; Victoria Guiote; Martinha Henrique; Felicidade Santiago Journal: An Bras Dermatol Date: 2022-08-31 Impact factor: 2.113